2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

322. Hemophilia A and B: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Gene Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Surgical, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Practice Models, Telemedicine, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Genetic Disorders, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1275 Differences in primary total knee arthroplasty among females and males with hemophilia in the United States: An analysis of Medicare data

Mohamad Ali Tfaily, MD MS, Tinatin Muradashvili, MD2, Stefanie M. Digiandomenico, MD MS3, Christine Kempton, MD, MSc4, Stacey Fedewa, PhD5
1 Emory University, Atlanta, Georgia, United States
2 Emory University, Atlanta, Georgia, United States
3 Emory University, Atlanta, Georgia, United States
4 Emory University, Atlanta, Georgia, United States, Emory University, Atlanta, Georgia, United States
5 Emory University, Atlanta, Georgia, United States, Emory University, Atlanta, Georgia, United States

Introduction: Hemophilia is a hereditary bleeding disorder mostly affecting males, though its symptomatic burden is being increasingly recognized among females. A complication of hemophilia is joint disease leading to joint arthroplasty, commonly total knee arthroplasty (TKA). Sex-specific occurrence and risk factors of TKA in people with hemophilia (PwH) are not well described but are needed to inform multidisciplinary care in hemophilia treatment centers (HTCs). This study aims to determine the prevalence of primary TKA among males and females with hemophilia compared to the general population. 

Methods: A validated algorithm and diagnostic codes were used to identify PwH in the United States Medicare Claims database who were ≥65 years and <65 years with disabilities covered by Medicare Parts A and B between 2000 and 2020. Each PwH was followed from Medicare enrollment to their first TKA, disenrollment, or death and was matched by birth year and sex to 4 individuals from the general population. Generalized estimated equations were used to estimate unadjusted and adjusted risk ratios (aRR) and 95% confidence intervals (CI) for TKA among PwH and the matched general population. Obesity and Charlson Comorbidity Index (CCI) were defined using diagnostic codes.  

Results: We identified 2,361 PwH, with an average age of 54.7 years, and 9.9% underwent TKA. There were 304 females with hemophilia, of whom 38 (12.5%) underwent TKA; among 2,057 males with hemophilia, 195 (9.5%) underwent TKA (p=.1). Predictors of TKA in the hemophilia cohort included obesity (aRR=1.72; 95% CI 1.27 – 2.32; p<.01), whereas race, CCI, and hemophilia type (A vs B) were not significantly associated with TKA.  When compared with the matched general population, TKA risk in PwH was significantly higher overall (aRR=2.19, 95%CI 2.01-2.82, p<.1) after adjusting for CCI, race, and obesity. In the sex-stratified analyses, females (aRR=1.77, 95%CI 1.23-2.54, p<.01) and males (aRR=2.28, 95%CI 1.92-2.70, p<.01) had significantly higher risk of TKA compared with the general population after adjusting for CCI, race, and obesity.   

Conclusions: Overall, 1 in 10 PwH received a TKA, a risk approximately two times greater than the general population. This higher risk was observed in both females and males with hemophilia, suggesting joint damage in both sexes. This highlights the ongoing need for multidisciplinary approaches to guide treatment plans within the aging hemophilia population, especially as females with hemophilia are being increasingly recognized.  

Mohamad Ali Tfaily, MD MS: No relevant conflicts of interest to declare.